Mirna Therapeutics Inc. (MIRN) Stock Price Down 13.4%
Mirna Therapeutics Inc. (NASDAQ:MIRN) shares were down 13.4% during trading on Tuesday . The company traded as low as $2.38 and last traded at $2.59, with a volume of 102,668 shares trading hands. The stock had previously closed at $2.99.
A number of research analysts recently commented on MIRN shares. Zacks Investment Research upgraded Mirna Therapeutics from a “hold” rating to a “buy” rating and set a $5.00 target price for the company in a research note on Thursday, July 14th. Cantor Fitzgerald restated a “buy” rating and issued a $14.00 target price on shares of Mirna Therapeutics in a research note on Friday, May 13th. Leerink Swann lowered Mirna Therapeutics from an “outperform” rating to a “market perform” rating and cut their target price for the company from $10.00 to $4.00 in a research note on Monday, August 15th. Citigroup Inc. lowered Mirna Therapeutics from a “buy” rating to a “neutral” rating and cut their target price for the company from $7.00 to $4.50 in a research note on Tuesday, August 16th. Finally, Oppenheimer Holdings Inc. upped their target price on Mirna Therapeutics from $7.00 to $13.00 and gave the company an “outperform” rating in a research note on Tuesday, August 16th. Three analysts have rated the stock with a hold rating and two have issued a buy rating to the company. The stock has an average rating of “Hold” and a consensus price target of $8.10.
The company’s market capitalization is $50.00 million. The stock has a 50-day moving average of $3.99 and a 200-day moving average of $4.30.
Mirna Therapeutics, Inc is a United States-based clinical-stage biopharmaceutical company. The Company is focused on developing a pipeline of microRNA (ribonucleic acid)-based oncology therapeutics. It is developing a cancer therapy, microRNA Replacement Therapy, focused on replacing naturally occurring microRNAs that are under expressed in cancer cells with microRNA mimics.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.